BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.

Weijia WangShanzhi HeWenli ZhangHongyu ZhangVincent M DeStefanoMasayuki WadaKevin PinzGreg DeenerDarshi ShahNabil HagagMin WangMing HongRonghao ZengTing LanYu MaFugui LiYingwen LiangZhencong GuoChanjuan ZouMingxia WangLing DingYupo MaYong Yuan

Published in: Annals of the rheumatic diseases (2024)

Data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in patients with SLE.

Keyphrases

systemic lupus erythematosus
open label
clinical trial
phase ii
disease activity
phase iii
study protocol
phase ii study
electronic health record
big data
randomized controlled trial
data analysis
radiation therapy
squamous cell carcinoma
cell therapy
bone marrow
deep learning